What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.

Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several year...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Testa, L, Bhindi, R, Van Gaal, W, Latini, R, Pizzocri, S, Lanotte, S, Biondi Zoccai, G, Valgimigli, M, Laudisa, M, Brambilla, N, Banning, A, Bedogni, F
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2010

Gelijkaardige items

Drug eluting stents versus bare metal stents in the treatment of saphenous vein graft disease: a systematic review and meta-analysis.
door: Testa, L, et al.
Gepubliceerd in: (2010)

Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents
door: L. Testa, et al.
Gepubliceerd in: (2010-01-01)

Use of prasugrel in patients with clopidogrel hypersensitivity
door: Aparna Joshi, et al.
Gepubliceerd in: (2022-01-01)

Interaction between statins and clopidogrel: is there anything clinically relevant?
door: Bhindi, R, et al.
Gepubliceerd in: (2008)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
door: Satoshi Niijima, et al.
Gepubliceerd in: (2018-03-01)

Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
door: Testa, L, et al.
Gepubliceerd in: (2009)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
door: Dongwhane Lee, et al.
Gepubliceerd in: (2018-09-01)

Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders
door: Philip M Bath, et al.
Gepubliceerd in: (2018-07-01)

Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis
door: Gerhard Selhorst, et al.
Gepubliceerd in: (2019-04-01)

Repeat thrombolysis or conservative therapy vs. rescue percutaneous coronary intervention for failed thrombolysis: systematic review and meta-analysis.
door: Testa, L, et al.
Gepubliceerd in: (2008)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
door: Jan Kiebist, et al.
Gepubliceerd in: (2021-09-01)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
door: Jim McLenachan, et al.
Gepubliceerd in: (2019-05-01)

In silico Investigation on Clopidogrel, Prasugrel and Ticagrelor as Potential Mono Antiplatelet Therapy for Acute Coronary Syndrome
door: Muhammad Naufal Hibatullah, et al.
Gepubliceerd in: (2024-11-01)

Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study
door: Feng-Yu Kuo, et al.
Gepubliceerd in: (2022-09-01)

Prasugrel
door: Gianluca Airoldi, et al.
Gepubliceerd in: (2013-04-01)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Gepubliceerd in: (2019-07-01)

Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
door: Bartosz Olechowski, et al.
Gepubliceerd in: (2016-01-01)

Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment
door: Monica Verdoia, et al.
Gepubliceerd in: (2019-10-01)

Study to assess improvement in therapeutic outcomes by platelet inhibition with prasugrel
door: Amit Madaan
Gepubliceerd in: (2015-12-01)

Low-dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms: Follow-up of over 6 Months
door: Dongwhane Lee, et al.
Gepubliceerd in: (2019-03-01)

Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.
door: Testa, L, et al.
Gepubliceerd in: (2008)

Clopidogrel, ticagrelor, prasugrel or an alternation of two P2Y12 in patients with acute myocardial infarction with cardiogenic shock
door: Vojko Kanic, et al.
Gepubliceerd in: (2024-01-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
door: Yuri Kim, et al.
Gepubliceerd in: (2023-01-01)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
door: Yuri Kim, et al.
Gepubliceerd in: (2023-01-01)

Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low‐Dose Prasugrel or Clopidogrel
door: Gabriele Crimi, et al.
Gepubliceerd in: (2019-01-01)

Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication
door: Constance C. F. M. J. Baaten, et al.
Gepubliceerd in: (2015-09-01)

Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery.
door: Testa, L, et al.
Gepubliceerd in: (2009)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
door: Shokoufeh Hajsadeghi, et al.
Gepubliceerd in: (2016-01-01)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
door: Shokoufeh Hajsadeghi, et al.
Gepubliceerd in: (2016-08-01)

The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance
door: John I. Louca, et al.
Gepubliceerd in: (2014-09-01)

NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS
door: P. S. LAGUTA, et al.
Gepubliceerd in: (2017-12-01)

Legacy of blood: does prasugrel inhibit megakaryocytes and do juvenile platelets inherit this inhibition?
door: Carlos G. Santos-Gallego
Gepubliceerd in: (2015-09-01)

The hurdles of translating a single-center observation into practice.
door: Testa, L, et al.
Gepubliceerd in: (2008)

Digitalis: a dangerous drug in atrial fibrillation?
door: Testa, L, et al.
Gepubliceerd in: (2008)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
door: Lulu Dai, et al.
Gepubliceerd in: (2022-06-01)

Mortality in primary angioplasty patients starting antiplatelet therapy with prehospital prasugrel or clopidogrel: a 1-year follow-up from the European MULTIPRAC Registry
door: Goldstein P, et al.
Gepubliceerd in: (2016-04-01)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
door: Zhe Wang, et al.
Gepubliceerd in: (2020-03-01)

The effect of concurrent clopidogrel and omeprazole administration on clopidogrel metabolism and platelet function in healthy cats
door: Christina Plante, et al.
Gepubliceerd in: (2024-11-01)

Sepsis favors high-on-clopidogrel platelet reactivity
door: Karolina Akinosoglou, et al.
Gepubliceerd in: (2018-01-01)

Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders
door: Wiktor Kuliczkowski, et al.
Gepubliceerd in: (2021-01-01)